Incysus Announces Preclinical Data Presentations of γδ T Cell Immunotherapy Programs at Upcoming Medical Conferences

Academic partners at the University of Alabama at Birmingham (UAB), Emory University and the Children’s Hospital of Atlanta (CHOA) to highlight the Company’s programs

HAMILTON, Bermuda, March 24, 2017 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative off-the-shelf cellular therapy for the treatment of solid tumor cancers, and its partners will present preclinical data supporting the advancement of a γδ T cell therapy to the clinic. 

The research conducted at UAB provides a demonstration of the mechanisms related to a Drug Resistant Immunotherapy (DRI) using activated γδ T cells for treating cancer.  Incysus and UAB are moving quickly towards an investigational new drug application (IND) filing with the U.S. FDA to test the safety and efficacy of DRI γδ T cells in patients with glioblastoma.

“Solid tumors present unique therapeutic challenges related to immune-suppression and evasion due to the tumor microenvironment.  As immunotherapies move to new combinations, Incysus’ unique technology allows us to protect the viability of immune cells when used in combination with high-dose chemotherapy.  We use chemotherapy to shrink the tumor, kill immune-suppressive cells and to modify the tumor microenvironment, making it more amendable to our immunotherapy.  New cancer therapies are such an unmet need and we look forward to advancing these programs into patients,” said William Ho, Chief Executive Officer of Incysus.

Presentation details:

European Society for Blood and Marrow Transplantation (EBMT) 2017 - Marseille, France
March 27, 2017, 9:00 - 9:10am (CET)    
Oral Session 3: Novel drugs and immunotherapies – (
Title: Drug Resistant Lymphocyte Immunotherapy: Dose and Schedule Optimization
Presenter: Lawrence Lamb

American Association for Cancer Research (AACR) 2017 - Washington DC, USA
April 3, 2017, 8:00 - 12:00pm (EDT)
Session: PO.IM02.08 - Tumor Microenvironment and Checkpoints
Abstract # / Poster Board #: 1638 / 16 – (
Title: Improved outcomes with drug-resistant immunotherapy in a human xenograft model of glioblastoma multiforme
Authors: Samantha Langford, Harold Spencer, Anindya Dasgupta, George Y. Gillespie, Kathryn Sutton, Larisa Pereboeva, Lawrence Lamb

International Society for Cellular Therapy (ISCT) 2017 Annual Meeting - London, UK
May 3, 2017, 4:30 - 6:30pm (GMT)
Session: Corporate Symposium – Miltenyi Biotec – (
Title: Manufacturing of expanded/activated γδ T cells using the Miltenyi Prodigy® bioreactor system
Presenter: Lawrence Lamb

May 4, 2017, 5:00 - 6:30pm (GMT)
Poster Session 1
Abstract #: 2678636 
Title: Manufacturing of expanded/activated γδ T cells using the Miltenyi Prodigy® bioreactor system 
Authors: Sailesh Pillai, Samantha Langford, Joscelyn Bowersock, Ayman Saad, Lawrence Lamb

About Incysus, Ltd. 
Incysus is a Bermuda incorporated company focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer.  By using genetically modified γδ T cells, our technology addresses the challenges that immunotherapies face targeting cold, low mutation, cancers.  The Company's immuno-oncology programs with its collaborators include activated and gene modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells.


Contact Data